110 related articles for article (PubMed ID: 8636431)
1. Suppression of cell-mediated and humoral immune responses by an interleukin-2-immunoglobulin fusion protein in mice.
Kunzendorf U; Pohl T; Bulfone-Paus S; Krause H; Notter M; Onu A; Walz G; Diamantstein T
J Clin Invest; 1996 Mar; 97(5):1204-10. PubMed ID: 8636431
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of dichotomous action of IL-2-Pseudomonas exotoxin 40 (IL-2-PE40) on cell-mediated and humoral immune response.
Volk HD; Müller S; Yarkoni S; Diamantstein T; Lorberboum-Galski H
J Immunol; 1994 Sep; 153(6):2497-505. PubMed ID: 8077661
[TBL] [Abstract][Full Text] [Related]
3. Activation of human effector cells by a tumor reactive recombinant anti-ganglioside GD2 interleukin-2 fusion protein (ch14.18-IL2).
Hank JA; Surfus JE; Gan J; Jaeger P; Gillies SD; Reisfeld RA; Sondel PM
Clin Cancer Res; 1996 Dec; 2(12):1951-9. PubMed ID: 9816154
[TBL] [Abstract][Full Text] [Related]
4. Suppression of the cell-mediated immune response by a Fas-immunoglobulin fusion protein.
Shen Y; Young B; Lipman ML
Transplantation; 2006 Apr; 81(7):1041-8. PubMed ID: 16612282
[TBL] [Abstract][Full Text] [Related]
5. Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein.
Xu X; Clarke P; Szalai G; Shively JE; Williams LE; Shyr Y; Shi E; Primus FJ
Cancer Res; 2000 Aug; 60(16):4475-84. PubMed ID: 10969795
[TBL] [Abstract][Full Text] [Related]
6. Modulation of antigen-specific T cell response by a non-mitogenic anti-CD3 antibody.
Li J; Davis J; Bracht M; Carton J; Armstrong J; Gao W; Scallon B; Fung R; Emmell E; Zimmerman M; Griswold DE; Li L
Int Immunopharmacol; 2006 Jun; 6(6):880-91. PubMed ID: 16644473
[TBL] [Abstract][Full Text] [Related]
7. IL-2-IgG2b fusion protein suppresses murine contact hypersensitivity in vivo.
Rückert R; Brandt K; Hofmann U; Bulfone-Paus S; Paus R
J Invest Dermatol; 2002 Aug; 119(2):370-6. PubMed ID: 12190859
[TBL] [Abstract][Full Text] [Related]
8. Prolongation of corneal allograft survival by an interleukin-2-immunoglobulin fusion protein in mice.
Zhang EP; Pohl T; Bulfone-Paus S; Wachtlin J; Kunzendorf U; Hoffmann F
Graefes Arch Clin Exp Ophthalmol; 1998 Jul; 236(7):486-92. PubMed ID: 9672793
[TBL] [Abstract][Full Text] [Related]
9. An antagonistic IL-4 mutant prevents type I allergy in the mouse: inhibition of the IL-4/IL-13 receptor system completely abrogates humoral immune response to allergen and development of allergic symptoms in vivo.
Grunewald SM; Werthmann A; Schnarr B; Klein CE; Bröcker EB; Mohrs M; Brombacher F; Sebald W; Duschl A
J Immunol; 1998 Apr; 160(8):4004-9. PubMed ID: 9558109
[TBL] [Abstract][Full Text] [Related]
10. An IgG3-IL2 fusion protein activates complement, binds Fc gamma RI, generates LAK activity and shows enhanced binding to the high affinity IL-2R.
Harvill ET; Morrison SL
Immunotechnology; 1995 Aug; 1(2):95-105. PubMed ID: 9373338
[TBL] [Abstract][Full Text] [Related]
11. Evidence for a role of IL-17 in organ allograft rejection: IL-17 promotes the functional differentiation of dendritic cell progenitors.
Antonysamy MA; Fanslow WC; Fu F; Li W; Qian S; Troutt AB; Thomson AW
J Immunol; 1999 Jan; 162(1):577-84. PubMed ID: 9886435
[TBL] [Abstract][Full Text] [Related]
12. IL-2 induces in vivo suppression by CD4(+)CD25(+)Foxp3(+) regulatory T cells.
Brandenburg S; Takahashi T; de la Rosa M; Janke M; Karsten G; Muzzulini T; Orinska Z; Bulfone-Paus S; Scheffold A
Eur J Immunol; 2008 Jun; 38(6):1643-53. PubMed ID: 18493984
[TBL] [Abstract][Full Text] [Related]
13. CCL19-IgG prevents allograft rejection by impairment of immune cell trafficking.
Ziegler E; Gueler F; Rong S; Mengel M; Witzke O; Kribben A; Haller H; Kunzendorf U; Krautwald S
J Am Soc Nephrol; 2006 Sep; 17(9):2521-32. PubMed ID: 16899521
[TBL] [Abstract][Full Text] [Related]
14. Biological activities on T lymphocytes of a baculovirus-expressed chimeric recombinant IgG1 antibody with specificity for the CDR3-like loop on the D1 domain of the CD4 molecule.
Troadec S; Bès C; Chentouf M; Nguyen B; Briant L; Jacquet C; Chebli K; Pugnière M; Roquet F; Cerutti M; Chardès T
Clin Immunol; 2006 Apr; 119(1):38-50. PubMed ID: 16426893
[TBL] [Abstract][Full Text] [Related]
15. Periplocoside E, an effective compound from Periploca sepium Bge, inhibited T cell activation in vitro and in vivo.
Zhu YN; Zhao WM; Yang YF; Liu QF; Zhou Y; Tian J; Ni J; Fu YF; Zhong XG; Tang W; Zhou R; He PL; Li XY; Zuo JP
J Pharmacol Exp Ther; 2006 Feb; 316(2):662-9. PubMed ID: 16204471
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Th1 polarization by soluble TNF receptor is dependent on antigen-presenting cell-derived IL-12.
Becher B; Blain M; Giacomini PS; Antel JP
J Immunol; 1999 Jan; 162(2):684-8. PubMed ID: 9916686
[TBL] [Abstract][Full Text] [Related]
17. Expression of fusion IL2-B7.1(IgV+C) and effects on T lymphocytes.
Kong L; Li Y; Yang Y; Li K
Biochem Cell Biol; 2007 Dec; 85(6):685-95. PubMed ID: 18059527
[TBL] [Abstract][Full Text] [Related]
18. Vaccination with tumor cells engineered to secrete interleukin 2-immunoglobulin G fusion protein induces tumor rejection.
Bulfone-Paus S; von Bernuth H; Rückert R; Wachtlin J; Ungureanu D; Notter M; Krause H; Pohl T; Paus R; Kunzendorf U
Cancer Res; 1998 Jul; 58(13):2707-10. PubMed ID: 9661877
[TBL] [Abstract][Full Text] [Related]
19. Human IgG2 variants of chimeric anti-CD3 are nonmitogenic to T cells.
Cole MS; Anasetti C; Tso JY
J Immunol; 1997 Oct; 159(7):3613-21. PubMed ID: 9317161
[TBL] [Abstract][Full Text] [Related]
20. Efficient growth inhibition of ErbB2-overexpressing tumor cells by anti-ErbB2 ScFv-Fc-IL-2 fusion protein in vitro and in vivo.
Shi M; Zhang L; Gu HT; Jiang FQ; Qian L; Yu M; Chen GJ; Luo Q; Shen BF; Guo N
Acta Pharmacol Sin; 2007 Oct; 28(10):1611-20. PubMed ID: 17883948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
